Schedule 13D ownership disclosure

Atea Pharmaceuticals Inc

Common Stock, par value $0.001 per share · CUSIP: 04683R106

Event date: 2024-12-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BML Investment Partners, L.P.Reported CIK 0001373604

    Shares: 6,808,312 · Class: 8.1%

  • Leonard Braden MichaelReported CIK 0001373603

    Shares: 7,216,312 · Class: 8.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001373604-24-000114
Form type
SCHEDULE 13D
Filer
Atea Pharmaceuticals, Inc.
CIK
CIK 1593899
Filed
Dec 16, 2024
Reporting period
Dec 13, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub